BEAM

Company Overview — What Does Beam Therapeutics Inc. Do?

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Beam Therapeutics Inc. (BEAM) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO John Evans and employs approximately 510 people. With a market capitalization of $2.5B, BEAM is one of the notable companies in the Healthcare sector.

Beam Therapeutics Inc. (BEAM) Stock Rating — Reduce (April 2026)

As of April 2026, Beam Therapeutics Inc. receives a Reduce rating with a composite score of 33.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.BEAM ranks #3,203 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Beam Therapeutics Inc. ranks #483 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BEAM Stock Price and 52-Week Range

Beam Therapeutics Inc. (BEAM) currently trades at $27.35. The stock gained $1.02 (3.9%) in the most recent trading session. The 52-week high for BEAM is $36.44, which means the stock is currently trading -24.9% from its annual peak. The 52-week low is $13.53, putting the stock 102.2% above its annual trough. Recent trading volume was 1.5M shares, reflecting moderate market activity.

Is BEAM Overvalued or Undervalued? — Valuation Analysis

Beam Therapeutics Inc. (BEAM) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.01x, versus the sector average of 2.75x. The price-to-sales ratio is 62.51x, compared to 1.66x for the average Healthcare stock.

At current multiples, Beam Therapeutics Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Beam Therapeutics Inc. Profitability — ROE, Margins, and Quality Score

Beam Therapeutics Inc. (BEAM) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -34.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -28.4% versus the sector average of -33.1%.

On a margin basis, Beam Therapeutics Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -1267.5% (sector: -66.1%). Net profit margin stands at -1127.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -17.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

BEAM Debt, Balance Sheet, and Financial Health

Beam Therapeutics Inc. has a debt-to-equity ratio of 20.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 13.09x, indicating strong short-term liquidity. Total debt on the balance sheet is $1M. Cash and equivalents stand at $268M.

BEAM has a beta of 1.68, meaning it is more volatile than the broader market — a $10,000 investment in BEAM would be expected to move 68.1% more than the S&P 500 on any given day. The stability factor score for Beam Therapeutics Inc. is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Beam Therapeutics Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Beam Therapeutics Inc. reported revenue of $40M and earnings per share (EPS) of $-0.81. Net income for the quarter was $-421M. Gross margin was 100.0%. Operating income came in at $-473M.

In FY 2025, Beam Therapeutics Inc. reported revenue of $140M and earnings per share (EPS) of $-0.81. Net income for the quarter was $-80M. Revenue grew 120.0% year-over-year compared to FY 2024. Operating income came in at $-384M.

In Q3 2025, Beam Therapeutics Inc. reported revenue of $10M and earnings per share (EPS) of $-1.10. Net income for the quarter was $-113M. Revenue grew -32.0% year-over-year compared to Q3 2024. Operating income came in at $-127M.

In Q2 2025, Beam Therapeutics Inc. reported revenue of $8M and earnings per share (EPS) of $-1.00. Net income for the quarter was $-102M. Revenue grew -28.1% year-over-year compared to Q2 2024. Operating income came in at $-120M.

Over the past 8 quarters, Beam Therapeutics Inc. has demonstrated a growth trajectory, with revenue expanding from $12M to $40M. Investors analyzing BEAM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BEAM Dividend Yield and Income Analysis

Beam Therapeutics Inc. (BEAM) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BEAM Momentum and Technical Analysis Profile

Beam Therapeutics Inc. (BEAM) has a momentum factor score of 46/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 37/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 45/100 reflects moderate short selling activity.

BEAM vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Beam Therapeutics Inc. (BEAM) ranks #483 out of 838 stocks based on the Blank Capital composite score. This places BEAM in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BEAM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BEAM vs S&P 500 (SPY) comparison to assess how Beam Therapeutics Inc. stacks up against the broader market across all factor dimensions.

BEAM Next Earnings Date

No upcoming earnings date has been announced for Beam Therapeutics Inc. (BEAM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BEAM? — Investment Thesis Summary

The quantitative profile for Beam Therapeutics Inc. suggests caution. The quality score of 25/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. High volatility (stability score 31/100) increases portfolio risk.

In summary, Beam Therapeutics Inc. (BEAM) earns a Reduce rating with a composite score of 33.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BEAM stock.

Related Resources for BEAM Investors

Explore more research and tools: BEAM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BEAM head-to-head with peers: BEAM vs AZN, BEAM vs SLGL, BEAM vs VMD.